We have 2 of 27 papers
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
Gene expression analysis after BTK and PI3Kδ inhibitor treatment in chronic lymphocytic leukemia identifies cell‐surface CXCR4 as a synergistic target for combinatorial therapy
BTKi are preferred in clinical practice over idelalisib due to lower toxicity, but idelalisib plus anti ‐ CD20 antibodies remains relevant in the treatment of CLL cases resistant to BTKi and vene-toclax, in BTKi ‐ intolerant patients, and next ‐ generation PI3Ki such as duvelisib or umbralisib are being developed.